Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

1

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Synaptic vesicle glycoprotein 2A

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2016

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Epilepsy

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

UCB

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

FDA UNII

2

PUBCHEM

2

CHEBI

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antiepileptics

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

BRIVARACETAM

U863JGG2IA

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 2016

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Synaptic vesicle glycoprotein 2A

Conditions:

Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years...

of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.

ETIRACETAM, (R)-

73HC18Y1LW

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1